6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-3-carboxylic acid | 1219694-49-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-3-carboxylic acid
• 英文别名: 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-3-carboxylic acid
• CAS: 1219694-49-1
• 化学式: C₇H₈N₂O₃
• 分子量: 168.15
• InChiKey: XITXYOZZKMCGFO-UHFFFAOYSA-N

物化性质

• 沸点：
  418.4±45.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Chemical Compounds
  申请人：AstraZeneca AB

  公开号：US20160376287A1

  公开（公告）日：2016-12-29

  Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

  提供了一系列新颖的吡啶或嘧啶衍生物，可以抑制CDK9，并可能对治疗过度增殖性疾病有用。特别是这些化合物在治疗增殖性疾病方面具有用途，如癌症，包括血液恶性肿瘤，如急性髓细胞白血病，多发性骨髓瘤，慢性淋巴细胞白血病，弥漫性大B细胞淋巴瘤，Burkitt淋巴瘤，滤泡性淋巴瘤以及实体肿瘤，如乳腺癌，肺癌，神经母细胞瘤和结肠癌。
• Chemical compounds
  申请人：ASTRAZENECA AB

  公开号：US10717746B2

  公开（公告）日：2020-07-21

  Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

  本研究提供了一系列新型吡啶或嘧啶衍生物，它们能抑制 CDK9，可用于治疗增殖过快的疾病。特别是这些化合物可用于治疗增殖性疾病，如癌症，包括血液恶性肿瘤，如急性髓性白血病、多发性骨髓瘤、慢性淋巴细胞白血病、弥漫性大 B 细胞淋巴瘤、伯基特淋巴瘤、滤泡性淋巴瘤和实体瘤，如乳腺癌、肺癌、神经母细胞瘤和结肠癌。
• Pyridine and pyrimidine derivatives
  申请人：ASTRAZENECA AB

  公开号：US11352369B2

  公开（公告）日：2022-06-07

  Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

  本研究提供了一系列新型吡啶或嘧啶衍生物，它们能抑制 CDK9，可用于治疗增殖过快的疾病。特别是这些化合物可用于治疗增殖性疾病，如癌症，包括血液恶性肿瘤，如急性髓性白血病、多发性骨髓瘤、慢性淋巴细胞白血病、弥漫性大 B 细胞淋巴瘤、伯基特淋巴瘤、滤泡性淋巴瘤和实体瘤，如乳腺癌、肺癌、神经母细胞瘤和结肠癌。
• POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS
  申请人：Astrazeneca AB

  公开号：EP3313838B1

  公开（公告）日：2019-04-03
• CHEMICAL COMPOUNDS
  申请人：ASTRAZENECA AB

  公开号：US20180093998A1

  公开（公告）日：2018-04-05

  Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.